{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:51:42Z","timestamp":1776779502017,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04448-3","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:08Z","timestamp":1761900128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of 0.01% atropine and orthokeratology for incipient myopia: a 1-year retrospective study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9980-4268","authenticated-orcid":false,"given":"Xiaona","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"4448_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ophtha.2020.10.040","volume":"128","author":"BS Modjtahedi","year":"2021","unstructured":"Modjtahedi BS, Abbott RL, Fong DS, Lum F, Tan D, Task Force on M. Reducing the global burden of myopia by delaying the onset of myopia and reducing myopic progression in children: the academy\u2019s task force on myopia. Ophthalmology. 2021;128:816\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.040.","journal-title":"Ophthalmology"},{"key":"4448_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clae.2019.11.002","volume":"43","author":"JS Wolffsohn","year":"2020","unstructured":"Wolffsohn JS, Calossi A, Cho P, Gifford K, Jones L, Jones D, Guthrie S, Li M, Lipener C, Logan NS, Malet F, Peixoto-de-Matos SC, Gonzalez-Meijome JM, Nichols JJ, Orr JB, Santodomingo-Rubido J, Schaefer T, Thite N, van der Worp E, Tarutta E, Iomdina E, Ali BM, Villa-Collar C, Abesamis-Dichoso C, Chen C, Pult H, Blaser P, Parra Sandra Johanna G, Iqbal F, Ramos R, Carrillo Orihuela G, Boychev N. Global trends in myopia management attitudes and strategies in clinical practice \u2013\u20092019 update. Cont Lens Anterior Eye. 2020;43:9\u201317. https:\/\/doi.org\/10.1016\/j.clae.2019.11.002.","journal-title":"Cont Lens Anterior Eye"},{"key":"4448_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global prevalence of myopia and high myopia and Temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006.","journal-title":"Ophthalmology"},{"key":"4448_CR4","doi-asserted-by":"publisher","first-page":"e048450","DOI":"10.1136\/bmjopen-2020-048450","volume":"11","author":"X He","year":"2021","unstructured":"He X, Sankaridurg P, Xiong S, Li W, Naduvilath T, Lin S, Weng R, Lv M, Ma Y, Lu L, Wang J, Zhao R, Resnikoff S, Zhu J, Zou H, Xu X. Prevalence of myopia and high myopia, and the association with education: Shanghai child and adolescent Large-scale eye study (SCALE): a cross-sectional study. BMJ Open. 2021;11:e048450. https:\/\/doi.org\/10.1136\/bmjopen-2020-048450.","journal-title":"BMJ Open"},{"key":"4448_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: A review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020;61:49. https:\/\/doi.org\/10.1167\/iovs.61.4.49.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4448_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128:1561\u201379. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.032.","journal-title":"Ophthalmology"},{"key":"4448_CR7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062.","journal-title":"Ophthalmology"},{"key":"4448_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the treatment of myopia 2). Ophthalmology. 2012;119:347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"key":"4448_CR9","doi-asserted-by":"publisher","unstructured":"Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157:451\u2013457 e451 https:\/\/doi.org\/10.1016\/j.ajo.2013.09.020","DOI":"10.1016\/j.ajo.2013.09.020"},{"key":"4448_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","volume":"131","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, Chen LJ, Pang CP, Yam JC. Five-Year clinical trial of the Low-Concentration Atropine for myopia progression (LAMP) study: phase 4 report. Ophthalmology. 2024;131:1011\u201320. https:\/\/doi.org\/10.1016\/j.ophtha.2024.03.013.","journal-title":"Ophthalmology"},{"key":"4448_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.14744\/bej.2022.07742","volume":"7","author":"R Kaiti","year":"2022","unstructured":"Kaiti R, Shyangbo R, Sharma IP. Role of Atropine in the control of myopia Progression- A review. Beyoglu Eye J. 2022;7:157\u201366. https:\/\/doi.org\/10.14744\/bej.2022.07742.","journal-title":"Beyoglu Eye J"},{"key":"4448_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ophtha.2014.09.028","volume":"122","author":"HA Swarbrick","year":"2015","unstructured":"Swarbrick HA, Alharbi A, Watt K, Lum E, Kang P. Myopia control during orthokeratology lens wear in children using a novel study design. Ophthalmology. 2015;122:620\u201330. https:\/\/doi.org\/10.1016\/j.ophtha.2014.09.028.","journal-title":"Ophthalmology"},{"key":"4448_CR13","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1167\/iovs.12-10565","volume":"53","author":"P Cho","year":"2012","unstructured":"Cho P, Cheung SW. Retardation of myopia in orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53:7077\u201385. https:\/\/doi.org\/10.1167\/iovs.12-10565.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4448_CR14","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1167\/iovs.10-5485","volume":"52","author":"T Kakita","year":"2011","unstructured":"Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Vis Sci. 2011;52:2170\u20134. https:\/\/doi.org\/10.1167\/iovs.10-5485.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4448_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ophtha.2018.11.026","volume":"126","author":"DK VanderVeen","year":"2019","unstructured":"VanderVeen DK, Kraker RT, Pineles SL, Hutchinson AK, Wilson LB, Galvin JA, Lambert SR. Use of orthokeratology for the prevention of myopic progression in children: A report by the American academy of ophthalmology. Ophthalmology. 2019;126:623\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.026.","journal-title":"Ophthalmology"},{"key":"4448_CR16","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/bjo-2022-321272","volume":"107","author":"S Xu","year":"2023","unstructured":"Xu S, Li Z, Zhao W, Zheng B, Jiang J, Ye G, Feng Z, Long W, He L, He M, Hu Y, Yang X. Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial. Br J Ophthalmol. 2023;107:1812\u20137. https:\/\/doi.org\/10.1136\/bjo-2022-321272.","journal-title":"Br J Ophthalmol"},{"key":"4448_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2415-14-40","volume":"14","author":"HJ Lin","year":"2014","unstructured":"Lin HJ, Wan L, Tsai FJ, Tsai YY, Chen LA, Tsai AL, Huang YC. Overnight orthokeratology is comparable with Atropine in controlling myopia. BMC Ophthalmol. 2014;14:40. https:\/\/doi.org\/10.1186\/1471-2415-14-40.","journal-title":"BMC Ophthalmol"},{"key":"4448_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/ICL.0000000000000699","volume":"47","author":"Y Lyu","year":"2021","unstructured":"Lyu Y, Ji N, Fu AC, Wang WQ, Wei L, Qin J, Zhao BX. Comparison of administration of 0.02% Atropine and orthokeratology for myopia control. Eye Contact Lens. 2021;47:81\u20135. https:\/\/doi.org\/10.1097\/ICL.0000000000000699.","journal-title":"Eye Contact Lens"},{"key":"4448_CR19","doi-asserted-by":"publisher","unstructured":"Wan L, Wei CC, Chen CS, Chang CY, Lin CJ, Chen JJ, Tien PT, Lin HJ. The synergistic effects of orthokeratology and atropine in slowing the progression of myopia. J Clin Med. 2018;7. https:\/\/doi.org\/10.3390\/jcm7090259","DOI":"10.3390\/jcm7090259"},{"key":"4448_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-018-0608-3","volume":"62","author":"N Kinoshita","year":"2018","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and Atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544\u201353. https:\/\/doi.org\/10.1007\/s10384-018-0608-3.","journal-title":"Jpn J Ophthalmol"},{"key":"4448_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","volume":"40","author":"Q Tan","year":"2020","unstructured":"Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% Atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557\u201366. https:\/\/doi.org\/10.1111\/opo.12722.","journal-title":"Ophthalmic Physiol Opt"},{"key":"4448_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/08164622.2021.1943318","volume":"105","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhao G, Li Y. Adjunctive effects of orthokeratology and Atropine 0.01% eye drops on slowing the progression of myopia. Clin Exp Optom. 2022;105:520\u20136. https:\/\/doi.org\/10.1080\/08164622.2021.1943318.","journal-title":"Clin Exp Optom"},{"key":"4448_CR23","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.clae.2022.101723","volume":"46","author":"Q Tan","year":"2023","unstructured":"Tan Q, Ng AL, Cheng GP, Woo VC, Cho P. Combined 0.01% Atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Cont Lens Anterior Eye. 2023;46:101723. https:\/\/doi.org\/10.1016\/j.clae.2022.101723.","journal-title":"Cont Lens Anterior Eye"},{"key":"4448_CR24","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, Kakehashi A. Efficacy of combined orthokeratology and 0.01% Atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:12750. https:\/\/doi.org\/10.1038\/s41598-020-69710-8.","journal-title":"Sci Rep"},{"key":"4448_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10792-020-01658-0","volume":"41","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Hao Q. Clinical efficacy of 0.01% Atropine in retarding the progression of myopia in children. Int Ophthalmol. 2021;41:1011\u20137. https:\/\/doi.org\/10.1007\/s10792-020-01658-0.","journal-title":"Int Ophthalmol"},{"key":"4448_CR26","doi-asserted-by":"publisher","first-page":"e38384","DOI":"10.1097\/MD.0000000000038384","volume":"103","author":"Y Guo","year":"2024","unstructured":"Guo Y, Liu Y, Hu Z, Li Y, Zhang H, Zhao S. Efficacy and safety of 0.01% Atropine combined with orthokeratology lens in delaying juvenile myopia: an observational study. Med (Baltim). 2024;103:e38384. https:\/\/doi.org\/10.1097\/MD.0000000000038384.","journal-title":"Med (Baltim)"},{"key":"4448_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, Swaminathan M, Phuljhele S, Velpandian T, Sharma N. Atropine for the treatment of childhood myopia in india: multicentric randomized trial. Ophthalmology. 2021;128:1367\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2021.01.026.","journal-title":"Ophthalmology"},{"key":"4448_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-Concentration Atropine for myopia progression (LAMP) study: A Randomized, Double-Blinded, Placebo-Controlled trial of 0.05%, 0.025%, and 0.01% Atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"key":"4448_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, Lang E, Hemmati HD, Chandler SP, Investigators CTG. Efficacy and safety of 0.01% and 0.02% Atropine for the treatment of pediatric myopia progression over 3 years: A randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2097.","journal-title":"JAMA Ophthalmol"},{"key":"4448_CR30","doi-asserted-by":"publisher","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, Kehler LAF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA, Pediatric Eye Disease Investigator G. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2855","DOI":"10.1001\/jamaophthalmol.2023.2855"},{"key":"4448_CR31","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.11-8453","volume":"53","author":"T Hiraoka","year":"2012","unstructured":"Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913\u20139. https:\/\/doi.org\/10.1167\/iovs.11-8453.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4448_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/02713680590907256","volume":"30","author":"P Cho","year":"2005","unstructured":"Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong kong: a pilot study on refractive changes and myopic control. Curr Eye Res. 2005;30:71\u201380. https:\/\/doi.org\/10.1080\/02713680590907256.","journal-title":"Curr Eye Res"},{"key":"4448_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2011.0027","volume":"27","author":"PC Wu","year":"2011","unstructured":"Wu PC, Yang YH, Fang PC. The long-term results of using low-concentration Atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther. 2011;27:461\u20136. https:\/\/doi.org\/10.1089\/jop.2011.0027.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4448_CR34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.18240\/ijo.2018.10.13","volume":"11","author":"JS Moon","year":"2018","unstructured":"Moon JS, Shin SY. The diluted Atropine for Inhibition of myopia progression in Korean children. Int J Ophthalmol. 2018;11:1657\u201362. https:\/\/doi.org\/10.18240\/ijo.2018.10.13.","journal-title":"Int J Ophthalmol"},{"key":"4448_CR35","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1167\/iovs.11-8005","volume":"53","author":"J Santodomingo-Rubido","year":"2012","unstructured":"Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Myopia control with orthokeratology contact lenses in spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012;53:5060\u20135. https:\/\/doi.org\/10.1167\/iovs.11-8005.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4448_CR36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/bjo.2008.151365","volume":"93","author":"JJ Walline","year":"2009","unstructured":"Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol. 2009;93:1181\u20135. https:\/\/doi.org\/10.1136\/bjo.2008.151365.","journal-title":"Br J Ophthalmol"},{"key":"4448_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7150\/ijms.79496","volume":"20","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, Yin J, Li X, Hu M, Xue L, Zhang J, Zhou Y, Zhang X, Zhu Y, Zhong H. Effects of Long-Term wear and discontinuation of orthokeratology lenses on the eyeball parameters in children with myopia. Int J Med Sci. 2023;20:50\u20136. https:\/\/doi.org\/10.7150\/ijms.79496.","journal-title":"Int J Med Sci"},{"key":"4448_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-Year clinical trial on Atropine for the treatment of myopia 2: myopia control with Atropine 0.01% Eyedrops. Ophthalmology. 2016;123:391\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.004.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04448-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04448-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04448-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:09Z","timestamp":1761900129000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04448-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04448-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Beijing Children\u2019s Hospital, Beijing, China, and was performed in accordance with the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"610"}}